Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

T-cell engaging bispecific antibody shows potent MRD negativity with variable remission and survival outcomes: A bayesian meta-analysis of randomized controlled trials

View Full Paper
Ask AI
Bookmark
Share

Authors

HSHeer ShahKKKrish Keswani

Discussion

Loading...

Member takes

Overview

Bayesian meta-analysis reveals blinatumomab's effectiveness for MRD negativity and remission in B-ALL, suggesting improved treatment strategies.

Key Points

  • This analysis aims to evaluate the efficacy of blinatumomab in achieving MRD negativity and overall survival in B-ALL.
  • Conducted a Bayesian meta-analysis of three trials: TOWER, BLAST, and E1910.
  • Compared blinatumomab to standard chemotherapy and assessed outcomes such as CR, MRD negativity, and OS.
  • Implemented a random-effects hierarchical Bayesian model for analysis, with Markov Chain Monte Carlo simulations.
  • 1,009 patients were analyzed across the trials, indicating varying CR rates and concise estimates for each trial.
  • Blinatumomab demonstrated a significant advantage in achieving MRD negativity compared to standard treatments.
  • Average trends in overall survival were positive but lacked definitive evidence.

Cite This Study

Shah et al. (2025) studied this question.

synapsesocial.com/papers/69362f7f4fa91c937236e515https://doi.org/10.1182/blood-2025-6868
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Blinatumomab demonstrates MRD eradication in MRD-positive/chemotherapy-delayed pediatric B-ALL and high response in relapsed/refractory cases: a multicenter cohort study2025
  2. 2Safety and efficacy of consolidation-Phase blinatumomab in newly diagnosed B-cell acute lymphoblastic leukemia : A systematic review and meta-analysis2025
  3. 3Blinatumomab efficacy differs between newly diagnosed and relapsed/refractory B-ALL: Impact on MRD clearance and survival2025
  4. 4“upfront use of blinatumomab in adolescents and adults with Philadelphia Chromosome–Negative B-cell acute lymphoblastic leukemia: A systematic review and proportional meta-analysis”2025
  5. 5Blinatumomab vs. chemotherapy in pediatrics B-cell ALL: A meta-analysis of randomized controlled trials2025